Summary

Peptide API Market – Scope of Report
TMR’s report on the global peptide API market studies the past as well as the current growth trends and opportunities to gain valuable insights of the indicators of the market during the forecast period from 2024 to 2034. The report provides revenue of the global peptide API market for the period 2018–2034, considering 2024 as the base year and 2034 as the forecast year. The report also provides the compound annual growth rate (CAGR %) of the global peptide API market from 2024 to 2034.

The report has been prepared after an extensive research. Primary research involved bulk of the research efforts, wherein analysts carried out interviews with key opinion leaders, industry leaders, and opinion makers. Secondary research involved referring to key players’ product literature, annual reports, press releases, and relevant documents to understand the peptide API market.

Secondary research also included Internet sources, statistical data from government agencies, websites, and trade associations. Analysts employed a combination of top-down and bottom-up approaches to study various attributes of the global peptide API market.

The report includes an elaborate executive summary, along with a snapshot of the growth behavior of various segments included in the scope of the study. Moreover, the report throws light on the changing competitive dynamics in the global peptide API market. These serve as valuable tools for existing market players as well as for entities interested in participating in the global peptide API market.

The report delves into the competitive landscape of the global peptide API market. Key players operating in the global peptide API market have been identified and each one of these has been profiled in terms of various attributes. Company overview, financial standings, recent developments, and SWOT are the attributes of players in the global peptide API market profiled in this report.

Key Questions Answered in Global peptide API Market Report
• What is the sales/revenue generated by peptide API across all regions during the forecast period?
• What are the opportunities in the global peptide API market?
• What are the major drivers, restraints, opportunities, and threats in the market?
• Which regional market is set to expand at the fastest CAGR during the forecast period?
• Which segment is expected to generate the highest revenue globally in 2034?
• Which segment is projected to expand at the highest CAGR during the forecast period?
• What are the market positions of different companies operating in the global market?

Peptide API Market – Research Objectives and Research Approach
The comprehensive report on the global peptide API market begins with an overview, followed by the scope and objectives of the study. The report provides detailed explanation of the objectives behind this study and key vendors and distributors operating in the market and regulatory scenario for approval of products.

For reading comprehensibility, the report has been compiled in a chapter-wise layout, with each section divided into smaller ones. The report comprises an exhaustive collection of graphs and tables that are appropriately interspersed. Pictorial representation of actual and projected values of key segments is visually appealing to readers. This also allows comparison of the market shares of key segments in the past and at the end of the forecast period.

The report analyzes the global peptide API market in terms of product, end-user, and region. Key segments under each criterion have been studied at length, and the market share for each of these at the end of 2034 has been provided. Such valuable insights enable market stakeholders in making informed business decisions for investment in the global peptide API market.

ページTOPに戻る

Table of Contents

1. Preface
1.1. Market Definition and Scope
1.2. Market Segmentation
1.3. Key Research Objectives
1.4. Research Highlights
2. Assumptions and Research Methodology
3. Executive Summary : Global Peptide API Market
4. Market Overview
4.1. Introduction
4.1.1. Segment Definition
4.2. Overview
4.3. Market Dynamics
4.3.1. Drivers
4.3.2. Restraints
4.3.3. Opportunities
4.4. Global Peptide API Market Analysis and Forecasts, 2020-2034
4.4.1. Market Value (US$ Bn) and Volume Projections (Kg)
5. Key Insights
5.1. Epidemiology of Diabetes and Obesity across Key Countries / Regions
5.2. Recent Technological Advancements in GLP-1 Receptor Agonist Therapeutics Industry
5.3. Recent Technological Advancements in Insulin Therapeutics Industry
5.4. GLP-1 Receptor Agonist Therapeutics Pricing Trends
5.5. Insulin Therapeutics Pricing Trends
5.6. Clinical Trials Analysis
6. Global Peptide API Market Analysis and Forecasts, By Drug Class
6.1. Introduction & Definition
6.2. Key Findings / Developments
6.3. Market Value, Volume and Patient Population Forecast By Drug Class, 2020-2034
6.3.1. GLP-1 Receptor Agonist
6.3.2. Insulin
6.3.3. Other Peptide Classes
6.4. Market Attractiveness By Drug Class
7. Global Peptide API Market Analysis and Forecasts, By Product Type
7.1. Introduction & Definition
7.2. Key Findings / Developments
7.3. Market Value, Volume and Patient Population Forecast By Product Type, 2020-2034
7.3.1. GLP-1 Receptor Agonist Oral Formulations
7.3.2. GLP-1 Receptor Agonist Injectables
7.3.3. Insulin Injectables
7.3.4. Other Peptides
7.4. Market Attractiveness By Product Type
8. Global Peptide API Market Analysis and Forecasts, By Route of Administration
8.1. Introduction & Definition
8.2. Key Findings / Developments
8.3. Market Value, Volume and Patient Population Forecast By Route of Administration, 2020-2034
8.3.1. Oral
8.3.2. Parenteral
8.4. Market Attractiveness By Route of Administration
9. Global Peptide API Market Analysis and Forecasts, By Application
9.1. Introduction & Definition
9.2. Key Findings / Developments
9.3. Market Value, Volume and Patient Population Forecast By Application, 2020-2034
9.3.1. Type 2 Diabetes Mellitus
9.3.2. Type 1 Diabetes
9.3.3. Obesity
9.3.4. Non-alcoholic Fatty Liver Disease
9.3.5. Others
9.4. Market Attractiveness By Application
10. Global Peptide API Market Analysis and Forecasts, By Region
10.1. Key Findings
10.2. Market Value, Volume and Patient Population Forecast By Region
10.2.1. North America
10.2.2. Europe
10.2.3. Asia Pacific
10.2.4. Latin America
10.2.5. Middle East & Africa
10.3. Market Attractiveness By Region
11. North America Peptide API Market Analysis and Forecast
11.1. Introduction
11.1.1. Key Findings
11.2. Market Value, Volume and Patient Population Forecast By Drug Class, 2020-2034
11.2.1. GLP-1 Receptor Agonist
11.2.2. Insulin
11.2.3. Other Peptide Classes
11.3. Market Value, Volume and Patient Population Forecast By Product Type, 2020-2034
11.3.1. GLP-1 Receptor Agonist Oral Formulations
11.3.2. GLP-1 Receptor Agonist Injectables
11.3.3. Insulin Injectables
11.3.4. Other Peptides
11.4. Market Value, Volume and Patient Population Forecast By Route of Administration, 2020-2034
11.4.1. Oral
11.4.2. Parenteral
11.5. Market Value, Volume and Patient Population Forecast By Application, 2020-2034
11.5.1. Type 2 Diabetes Mellitus
11.5.2. Type 1 Diabetes
11.5.3. Obesity
11.5.4. Non-alcoholic Fatty Liver Disease
11.5.5. Others
11.6. Market Value, Volume and Patient Population Forecast By Country, 2020-2034
11.6.1. U.S.
11.6.2. Canada
12. Competition Landscape
12.1. Market Player - Competition Matrix (By Tier and Size of companies)
12.2. Market Share Analysis By Company (2023)
12.3. Competitive Dashboard
12.3.1. By Region
12.3.2. By Drug Class
12.4. Competitive Snapshot
12.5. Company Profiles
12.5.1. Eli Lilly and Company
12.5.1.1. Company Overview
12.5.1.2. Financial Overview
12.5.1.3. Product Portfolio
12.5.1.4. Business Strategies
12.5.1.5. Recent Developments
12.5.2. Sanofi S.A.
12.5.2.1. Company Overview
12.5.2.2. Financial Overview
12.5.2.3. Product Portfolio
12.5.2.4. Business Strategies
12.5.2.5. Recent Developments
12.5.3. Novo Nordisk
12.5.3.1. Company Overview
12.5.3.2. Financial Overview
12.5.3.3. Product Portfolio
12.5.3.4. Business Strategies
12.5.3.5. Recent Developments
12.5.4. AstraZeneca
12.5.4.1. Company Overview
12.5.4.2. Financial Overview
12.5.4.3. Product Portfolio
12.5.4.4. Business Strategies
12.5.4.5. Recent Developments
12.5.5. GlaxoSmithKline
12.5.5.1. Company Overview
12.5.5.2. Financial Overview
12.5.5.3. Product Portfolio
12.5.5.4. Business Strategies
12.5.5.5. Recent Developments
12.5.6. PegBio Co. Ltd.
12.5.6.1. Company Overview
12.5.6.2. Financial Overview
12.5.6.3. Product Portfolio
12.5.6.4. Business Strategies
12.5.6.5. Recent Developments
12.5.7. Amgen Inc.
12.5.7.1. Company Overview
12.5.7.2. Financial Overview
12.5.7.3. Product Portfolio
12.5.7.4. Business Strategies
12.5.7.5. Recent Developments
12.5.8. Pfizer Inc.
12.5.8.1. Company Overview
12.5.8.2. Financial Overview
12.5.8.3. Product Portfolio
12.5.8.4. Business Strategies
12.5.8.5. Recent Developments
12.5.9. Innovent Biologics, Inc.
12.5.9.1. Company Overview
12.5.9.2. Financial Overview
12.5.9.3. Product Portfolio
12.5.9.4. Business Strategies
12.5.9.5. Recent Developments
12.5.10. Sun Pharmaceutical Industries Limited
12.5.10.1. Company Overview
12.5.10.2. Financial Overview
12.5.10.3. Product Portfolio
12.5.10.4. Business Strategies
12.5.10.5. Recent Developments
12.5.11. Boehringer Ingelheim
12.5.11.1. Company Overview
12.5.11.2. Financial Overview
12.5.11.3. Product Portfolio
12.5.11.4. Business Strategies
12.5.11.5. Recent Developments
12.5.12. Biocon Limited
12.5.12.1. Company Overview
12.5.12.2. Financial Overview
12.5.12.3. Product Portfolio
12.5.12.4. Business Strategies
12.5.12.5. Recent Developments
12.5.13. Wockhardt
12.5.13.1. Company Overview
12.5.13.2. Financial Overview
12.5.13.3. Product Portfolio
12.5.13.4. Business Strategies
12.5.13.5. Recent Developments